ELAVL1 and Parkinson disease: This regulatory network provides an option for therapeutic intervention in PD, as increased levels and aggregation of α-synuclein are a hallmark of this disease, and miR-7 biogenesis via HuR might be targeted to impact SNCA expression (Poewe et al., 2017).